natgillin/translations-raw huggingface dataset:
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5% CI 0.90 - 1.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Pokazalo se da je telmisartan slično učinkovit kao i ramipril u prethodno određenom sekundarnom ishodu uključujući kardiovaskularnu smrt, nefatalni infarkt miokarda i nefatalni moždani udar [0,99 (97,5% CI 0,90 – 1,08), p (neinferiornost) = 0,0004], u primarnom ishodu referentnog ispitivanja HOPE (The Heart Outcomes Prevention Evaluation Study) koje je ispitivalo učinak ramiprila u odnosu na placebo.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: nakon i intravenske ili peroralne primjene 14C označenog telmisartana većina primijenjene doze (>97 %) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: nakon i intravenske ili peroralne primjene 14C označenog telmisartana većina primijenjene doze (>97%) eliminira se u fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C označenog telmisartana, većina primijenjen doze (>97 %) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C označenog telmisartana, većina primijenjene doze (>97 %) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C označenog telmisartana, većina primijenjene doze (>97 %) eliminira se u fecesom putem bilijarne ekskrecije.
Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97 %) was eliminated in faeces via biliary excretion.
Telmisartan: Nakon i intravenske ili peroralne primjene 14C-označenog telmisartana, većina primijenjene doze (>97%) eliminira se fecesom putem bilijarne ekskrecije.
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 – 1.5 h after dosing.
Telmisartan: nakon peroralne primjene vršne koncentracije telmisartana postižu se 0,5-1,5 h nakon doziranja.
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 – 1.5 h after dosing.
Telmisartan: nakon peroralne primjene vršne koncetracije telmisartana postižu se 0,5-1,5 h nakon doziranja.
Telzir 50 mg/ml oral suspension
Telzir 50 mg/ml oralna suspenzija fosamprenavir
Telzir 700 mg film-coated tablets
Telzir 700 mg filmom obložene tablete
Telzir 700 mg film-coated tablets
Telzir 700 mg filmom obložene tablete fosamprenavir
Telzir does not require any other special storage conditions.
Telzir ne zahtijeva posebne uvjete čuvanja.
Telzir helps to control your condition, but it is not a cure for HIV infection.
Telzir pomaže u držanju Vašeg stanja pod kontrolom, ali neće izliječiti HIV infekciju.
Telzir is also available as a liquid (oral suspension) for people who are unable to swallow tablets. (Read the package leaflet of Telzir oral suspension for guidance on whether to take it with or without food.)
Telzir je također dostupan i u obliku tekućine (oralna suspenzija) za osobe koje ne mogu progutati tablete. (Pročitajte Uputu o lijeku koja dolazi s Telzir oralnom suspenzijom za smjernice o tome trebate li ga uzimati sa ili bez hrane.)
Telzir is also available as an oral suspension for use in patients unable to swallow tablets, and in paediatric patients less than 39 kg (please refer to the Summary of Product Characteristics for Telzir oral suspension).
Telzir je također dostupan i kao oralna suspenzija za primjenu kod bolesnika koji ne mogu progutati tablete i za djecu čija je tjelesna težina manja od 39 kg (molimo vidjeti Sažetak opisa svojstava lijeka za Telzir oralnu suspenziju).
Telzir is not recommended for children less than 6 years old.
Telzir se ne preporučuje za primjenu kod djece mlađe od 6 godina.
Telzir is supplied in plastic bottles containing 60 film-coated tablets.
Telzir je pakiran u plastične bočice koje sadrže 60 filmom obloženih tableta.
Telzir may require dose
Možda je potrebno smanjenje
Telzir may require dose reduction (using oral
Možda je potrebno smanjenje doze lijeka Telzir (primjenjujući
Telzir must not be administered concurrently with medicinal products with narrow therapeutic windows that are substrates of cytochrome P450 3A4 (CYP3A4), e.g. alfuzosin, amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergotamine, pimozide, quetiapine, quinidine, terfenadine, oral midazolam (for caution on parenterally administered midazolam, see section 4.5), oral triazolam, sildenafil used for the treatment of pulmonary arterial hypertension (for use of sildenafil in patients with erectile dysfunction, see sections 4.4 and 4.5).
Telzir se ne smije primjenjivati istodobno s lijekovima koji imaju usku terapijsku širinu, a koji su supstrati citokroma P450 3A4 (CYP3A4), npr. alfuzosin, amiodaron, astemizol, bepridil, cisaprid, dihidroergotamin, ergotamin, pimozid, kvetiapin, kinidin, terfenadin, oralni midazolam (za mjere opreza pri parenteralnoj primjeni midazolama, vidjeti dio 4.5), oralni triazolam, sildenafil koji se koristi za liječenje plućne arterijske hipertenzije (za primjenu sildenafila kod bolesnika s erektilnom disfunkcijom vidjeti dijelove 4.4 i 4.5).
Telzir oral suspension contains propyl and methyl parahydroxybenzoate.
Telzir oralna suspenzija sadrži propil i metil parahidroksibenzoat.
Telzir tablet and oral suspension formulations, both given fasted, delivered equivalent plasma amprenavir AUC values and the Telzir oral suspension formulation delivered a 14 % higher plasma amprenavir Cmax as compared to the oral tablet formulation.
Telzir u obliku tableta i oralne suspenzije, kada se oba oblika daju natašte, daje vrijednosti AUC ekvivalentne amprenaviru u plazmi, a Telzir u obliku oralne suspenzije davao je 14% viši Cmax amprenavira u plazmi od oralnih tableta.
Telzir with low doses of ritonavir is used in combination with other anti-retroviral medicines (‘combination therapy’) to treat adults, adolescents and children aged over 6 years infected with HIV.
Telzir s niskim dozama ritonavira koristi se u kombinaciji s drugim antiretrovirusnim lijekovima ("kombinirana terapija") u liječenju odraslih, adolescenata i djece u dobi iznad 6 godina koji su inficirani HIV-om.
Telzir with ritonavir must not be co-administered with medicinal products with narrow therapeutic windows that are highly dependent on CYP2D6 metabolism e.g. flecainide and propafenone (see section 4.5).
Telzir s ritonavirom ne smije se istodobno primjenjivati s lijekovima koji imaju usku terapijsku širinu, a koji su visoko ovisni o metabolizmu putem CYP2D6, poput flekainida i propafenona (vidjeti dio 4.5).
Telzir with ritonavir must not be co-administered with medicinal products with narrow therapeutic windows that are highly dependent on CYP2D6 metabolism, e.g. flecainide and propafenone (see section 4.5).
Telzir s ritonavirom ne smije se istodobno primjenjivati s lijekovima koji imaju usku terapijsku širinu, a koji su visoko ovisni o metabolizmu putem CYP2D6, poput flekainida i propafenona (vidjeti dio 4.5).
Telzir with ritonavir should be used with caution and at reduced doses in adults with mild, moderate or severe hepatic impairment (see section 4.2).
Kod odraslih bolesnika s blagim, umjerenim ili teškim oštećenjem jetre Telzir s ritonavirom treba se primjenjivati oprezno i u smanjenim dozama (vidjeti dio 4.2).
Telzir).
(poput lijeka Telzir).
Telzir/ritonavir should not
imunosupresiva ne stabiliziraju, preporučuje se često praćenje
Temodal 100 mg capsules temozolomide
Temodal 100 mg kapsule temozolomid
Temodal 140 mg capsules temozolomide
Temodal 140 mg kapsule temozolomid
Temodal 180 mg capsules temozolomide
Temodal 180 mg kapsule temozolomid
Temodal 2.5 mg/ml powder for solution for infusion delivers equivalent TMZ dose and exposure to both TMZ and its active metabolite MTIC as the corresponding Temodal hard capsules (see section 5.2).
Primjenom lijeka Temodal 2,5 mg/ml prašak za otopinu za infuziju postižu se doza TMZ-a te izloženost TMZ-u i njegovu aktivnom metabolitu MTIC-u ekvivalentne onima koje se postižu odgovarajućom dozom Temodal tvrdih kapsula (vidjeti dio 5.2).
Temodal 20 mg capsules temozolomide
Temodal 20 mg kapsule temozolomid
Temodal 250 mg capsules temozolomide
Temodal 250 mg kapsule temozolomid
Temodal 5 mg capsules temozolomide
Temodal 5 mg kapsule temozolomid
Temodal is first used together with
Temodal se najprije
Temodal is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temodal je indiciran za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija. djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temodal is used for the treatment of specific forms of brain tumours: in adults with newly-diagnosed glioblastoma multiforme.
Temodal se koristi za liječenje određenih vrsta tumora mozga: u odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom.
Temodal monotherapy in recurrent or progressive glioma
Monoterapija lijekom Temodal u bolesnika s ponovnom pojavom ili pogoršanjem glioma
Temomedac 100 mg hard capsules temozolomide
Temomedac 100 mg tvrde kapsule temozolomid
Temomedac 100 mg hard capsules: gelatin, titanium dioxide (E 171), red iron oxide (E 172), shellac, propylene glycol and yellow iron oxide (E 172).
Temomedac 100 mg tvrde kapsule: želatina, titanijev dioksid (E 171), crveni željezov oksid (E 172), šelak, propilenglikol, žuti željezov oksid (E 172)
Temomedac 140 mg hard capsules temozolomide
Temomedac 140 mg tvrde kapsule temozolomid
Temomedac 140 mg hard capsules: gelatin, titanium dioxide (E 171), shellac, propylene glycol, indigo carmine (E 132) aluminium lake.
Temomedac 140 mg tvrde kapsule: želatina, titanijev dioksid (E 171), šelak, propilenglikol, indigo carmine (E 132) aluminium lake.
Temomedac 180 mg hard capsules temozolomide
Temomedac 180 mg tvrde kapsule temozolomid
Temomedac 20 mg hard capsules temozolomide
Temomedac 20 mg tvrde kapsule temozolomid
Temomedac 20 mg hard capsules: gelatine, titanium dioxide (E 171), shellac, propylene glycol, sunset yellow FCF aluminium Lake (E 110).
Temomedac 20 mg tvrde kapsule: želatina, titanijev dioksid (E 171), šelak,propilenglikol, sunset yellow FCF aluminium lake (E 110)
Temomedac 250 mg hard capsules temozolomide
Temomedac 250 mg tvrde kapsule temozolomid
Temomedac 5 mg hard capsules
Temomedac 5 mg tvrde kapsule
Temomedac 5 mg hard capsules Temomedac 20 mg hard capsules Temomedac 100 mg hard capsules Temomedac 140 mg hard capsules Temomedac 180 mg hard capsules Temomedac 250 mg hard capsules
Temomedac 5 mg tvrde kapsule Temomedac 20 mg tvrde kapsule Temomedac 100 mg tvrde kapsule Temomedac 140 mg tvrde kapsule Temomedac 180 mg tvrde kapsule Temomedac 250 mg tvrde kapsule
Temomedac 5 mg hard capsules temozolomide
Temomedac 5 mg tvrde kapsule temozolomid
Temomedac 5 mg hard capsules: gelatin, titanium dioxide (E 171), shellac, propylene glycol, indigo carmine (E 132) aluminium lake, yellow iron oxide (E 172)
Temomedac 5 mg tvrde kapsule: želatina, titanijev dioksid (E 171), šelak,propilenglikol, indigo carmine (E 132) aluminium lake, žuti željezov oksid (E 172)
Temomedac is a ‘generic medicine’.
Temomedac je „generički lijek“.
Temomedac is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temomedac je indiciran za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija. djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temomedac is used first with radiotherapy and then on its own; adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Temomedac se prvo koristi s radioterapijom, a potom sam; odrasli i djeca u dobi od tri godine i starija s malignim gliomom poput multiformnog glioblastoma ili anaplastičnog astracitoma kad se tumor vratio ili pogoršao nakon standardnog liječenja.
Temomedac is used for the treatment of specific forms of brain tumours: in adults with newly-diagnosed glioblastoma multiforme.
Temomedac se koristi za liječenje određenih vrsta tumora mozga: u odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom.
temozolomide
temozolomid (temozolomidum)
Temozolomide 100mg
Temozolomid 100 mg
Temozolomide 140mg
Temozolomid 140 mg
Temozolomide 180mg
Temozolomid 180 mg
Temozolomide 20mg
Temozolomid 20 mg
Temozolomide 250mg
Temozolomid 250 mg
Temozolomide 5mg
Temozolomid 5 mg
Temozolomide Accord 100 mg hard capsules have a white body, a pink cap, and are imprinted ‘TMZ’ on cap and ‘100’ on body with black ink.
Temozolomid Accord 100 mg tvrde kapsule imaju bijelo tijelo, ružičastu kapicu i crnom tintom otisnutu oznaku ˝TMZ˝na kapici i ˝100˝na tijelu.
Temozolomide Accord 100 mg hard capsules.
Temozolomid Accord 100 mg tvrde kapsule
Temozolomide Accord 140 mg hard capsules have a white body, a blue cap, and are imprinted ‘TMZ’ on cap and ‘140’ on body with black ink.
Temozolomid Accord 140 mg tvrde kapsule imaju bijelo tijelo, plavu kapicu i crnom tintom otisnutu oznaku ˝TMZ˝na kapici i ˝140˝na tijelu.
Temozolomide Accord 140 mg hard capsules.
Temozolomid Accord 140 mg tvrde kapsule
Temozolomide Accord 180 mg hard capsules have a white body, a maroon cap, and are imprinted ‘TMZ’ on cap and ‘180’ on body with black ink.
Temozolomid Accord 180 mg tvrde kapsule imaju bijelo tijelo, narančastu kapicu i crnom tintom otisnutu oznaku ˝TMZ˝na kapici i ˝180˝na tijelu.
Temozolomide Accord 180 mg hard capsules temozolomide
Temozolomid Accord 180 mg tvrde kapsule Temozolomid
Temozolomide Accord 180 mg hard capsules.
Temozolomid Accord 180 mg tvrde kapsule
Temozolomide Accord 20 mg hard capsules have a white body, a yellow cap, and are imprinted ‘TMZ’ on cap and ‘20’ on body with black ink.
Temozolomid Accord 20 mg tvrde kapsule imaju bijelo tijelo, žutu kapicu i crnom tintom otisnutu oznaku ˝TMZ˝na kapici i ˝20˝na tijelu.
Temozolomide Accord 20 mg hard capsules.
Temozolomid Accord 20 mg tvrde kapsule
Temozolomide Accord 250 mg hard capsules have a white body, a white cap, and are imprinted ‘TMZ’ on cap and ‘250’ on body with black ink.
Temozolomid Accord 250 mg tvrde kapsule imaju bijelo tijelo, bijelu kapicu i crnom tintom otisnutu oznaku ˝TMZ˝na kapici i ˝250˝na tijelu.
Temozolomide Accord 250 mg hard capsules temozolomide
Temozolomid Accord 250 mg tvrde kapsule temozolomid
Temozolomide Accord 250 mg hard capsules.
Temozolomid Accord 250 mg tvrde kapsule
Temozolomide Accord 5 mg hard capsules have a white body, a green cap, and are imprinted ‘TMZ’ on cap and ‘5’ on body with black ink.
Temozolomid Accord 5 mg tvrde kapsule imaju bijelo tijelo, zelenu kapicu i crnom tintom otisnutu oznaku ˝TMZ˝na kapici i ˝5˝na tijelu.
Temozolomide Accord 5 mg hard capsules temozolomide
Temozolomid Accord 5 mg tvrde kapsule Temozolomid
Temozolomide Accord 5 mg hard capsules.
Temozolomid Accord 5 mg tvrde kapsule
Temozolomide Accord capsules are taken to treat specific forms of brain tumours: adults with newly diagnosed specific form of brain tumour (glioblastoma multiforme).
Temozolomid Accord kapsule se koriste za liječenje specifičnih vrsta tumora mozga: odraslih bolesnika s novodijagnosticiranim specifičnim oblikom tumora mozga (multiformnim glioblastomom).
Temozolomide Accord is a ‘generic medicine’.
Temozolomide Accord je „generički lijek”.
Temozolomide Accord is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temozolomid Accord je indiciran za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija. djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Accord is used first with radiotherapy and then on its own; adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Temozolomide Accord se prvo koristi istodobno s radioterapijom, a zatim kao monoterapija; u odraslih bolesnika i djece od navršene tri godine starosti s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Accord is used to treat malignant glioma (brain tumours) in the following groups of patients: adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour).
Temozolomide Accord koristi se za liječenje malignih glioma (tumora mozga) u sljedećim grupama bolesnika: u odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom (agresivnim tipom malignog glioma).
Temozolomide Accord should be administered in the fasting state.
Temozolomid Accord tvrde kapsule moraju se uzimati natašte.
Temozolomide Accord should only be prescribed by physicians experienced in the oncological treatment of brain tumours.
Temozolomid Accord smiju propisivati samo liječnici s iskustvom u onkološkom liječenju tumora mozga.
Temozolomide Accord1 temozolomide
Temozolomide Accord1 temozolomid
Temozolomide Accordshould be administered in the fasting state.
Temozolomid Accord tvrde kapsule moraju se uzimati natašte.
Temozolomide Hexal
Hexal Temozolomide
Temozolomide Hexal
Temozolomide
Temozolomide Hexal 100 mg capsules Temozolomide
Temozolomid Hexal 100 mg kapsule temozolomid
Temozolomide Hexal 100 mg hard capsules Temozolomide
Temozolomid Hexal 100 mg tvrde kapsule temozolomid
Temozolomide Hexal 140 mg capsules Temozolomide
Temozolomid Hexal 140 mg kapsule temozolomid
Temozolomide Hexal 140 mg hard capsules Temozolomide
Temozolomid Hexal 140 mg tvrde kapsule temozolomid
Temozolomide Hexal 180 mg capsules Temozolomide
Temozolomid Hexal 180 mg kapsule temozolomid
Temozolomide Hexal 180 mg hard capsules Temozolomide
Temozolomid Hexal 180 mg tvrde kapsule temozolomid
Temozolomide Hexal 20 mg capsules Temozolomide
Temozolomid Hexal 20 mg kapsule temozolomid
Temozolomide Hexal 20 mg hard capsules Temozolomide
Temozolomid Hexal 20 mg tvrde kapsule temozolomid
Temozolomide Hexal 250 mg capsules Temozolomide
Temozolomid Hexal 250 mg kapsule temozolomid
Temozolomide Hexal 250 mg hard capsules Temozolomide
Temozolomid Hexal 250 mg tvrde kapsule temozolomid
Temozolomide Hexal 5 mg capsules Temozolomide
Temozolomid Hexal 5 mg kapsule temozolomid
Temozolomide Hexal 5 mg hard capsules Temozolomide
Temozolomid Hexal 5 mg tvrde kapsule temozolomid
Temozolomide Hexal is a ‘generic medicine’.
Temozolomide Hexal je „generički lijek”.
Temozolomide Hexal is administered in combination with focal radiotherapy (concomitant phase) followed by up to 6 cycles of temozolomide (TMZ) monotherapy (monotherapy phase).
Temozolomid Hexal se primjenjuje u kombinaciji s fokalnom radioterapijom (faza istodobnog liječenja), nakon čega slijedi do 6 ciklusa monoterapije temozolomidom (TMZ) (faza monoterapije).
Temozolomide Hexal is an anticancer medicine.
Temozolomide Hexal je citostatik.
Temozolomide Hexal is first used together with radiotherapy (concomitant phase of treatment) and after that alone (monotherapy phase of treatment). in children 3 years and older and adult patients with malignant glioma , such as glioblastoma multiforme or anaplastic astrocytoma.
Temozolomid Hexal se najprije koristi zajedno sa zračenjem (faza istodobnog liječenja), a zatim kao jedini lijek (faza monoterapije). u djece u dobi od 3 godine i starije te u odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom.
Temozolomide Hexal is indicated for the treatment of: adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment, children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Temozolomid Hexal indiciran je za liječenje: odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom, istodobno s radioterapijom (RT), a zatim kao monoterapija, djece od navršene tri godine starosti, adolescenata i odraslih bolesnika s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Hexal is used first with radiotherapy and then on its own; adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Temozolomide Hexal se prvo koristi istodobno s radioterapijom (RT), a zatim kao monoterapija; odraslih bolesnika i djece od navršene tri godine starosti s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
Temozolomide Hexal is used for the treatment of specific forms of brain tumours: in adults with newly-diagnosed glioblastoma multiforme.
Temozolomid Hexal se koristi za liječenje određenih vrsta tumora mozga: u odraslih s novodijagnosticiranim multiformnim glioblastomom.
Temozolomide Hexal should only be prescribed by physicians experienced in the oncological treatment of brain tumours.
Temozolomid Hexal smiju propisivati samo liječnici s iskustvom u onkološkom liječenju tumora mozga.
Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC).
Temozolomid je triazen koji se pri fiziološkom pH brzo kemijski pretvara u aktivni spoj monometil- triazenoimidazol-karboksamid (MTIC).